Celleration reaches key milestone of 1 million MIST® Therapy treatments

EDEN PRAIRIE, Minn., March 13, 2013 /PRNewswire/ -- Celleration, Inc., a privately held medical device company focused on developing and commercializing therapeutic ultrasound healing technologies to treat wounds, announced today that over 1 million MIST® Therapy treatments have been performed in the United States and U.K. benefiting more than 65,000 patients.   

MIST Therapy is low frequency ultrasound delivered through a saline mist to accelerate wound healing.  Unlike conventional wound treatments that are limited to treating the surface, MIST Therapy delivers ultrasound energy into and below the wound bed to stimulate cells and shorten the healing process.  "Having MIST Therapy available to treat complex wounds has allowed us to heal some of our most complex and recalcitrant ulcers," stated Christopher Attinger, MD, PhD, Professor of Plastic and Orthopedic Surgery, Georgetown University School of Medicine.  "Its ability to help reduce sustained inflammation and bacterial load has had a significant impact on many wound closure rates."  One such example is Alan Scott, wound care patient from Norwell, MA who commented, "MIST Therapy healed my leg wound after 7 years and almost a million dollars in other treatments failed."

In addition to being used to treat a wide range of acute and chronic wounds, MIST Therapy's unique ability to treat below the surface has allowed it to become the preferred early intervention for deep tissue injuries, a difficult to treat pressure ulcer that can degrade to a full thickness wound in a very short period of time.   Study results from two clinical trials were presented at the recent National Pressure Ulcer Advisory Panel meeting in Houston, TX, demonstrating the effectiveness of MIST in treating these difficult and costly wounds.   

"MIST Therapy consistently delivers excellent clinical outcomes in a cost effective manner.   These outcomes have led to high quality healthcare facilities fully adopting MIST Therapy in their wound care programs," stated Mark Wagner, President and CEO of Celleration, Inc.  "In today's changing environment, it is no longer acceptable to simply treat a wound, but you must cost effectively heal a wound, which is where MIST Therapy is making a difference." 

In addition to reaching the 1 million treatment milestone in early 2013, Celleration closed a $7.0 million round of equity financing that was fully subscribed, to support additional clinical trials and the development of its next generation platform. 

About Celleration, Inc.:
Celleration, Inc. is a privately held medical device company. Celleration develops and markets a proprietary technology that has been proven to accelerate healing in wounds by delivering therapeutic, low frequency ultrasound without direct contact of the delivery device to the wound surface. Celleration's core product, the MIST Therapy® System has been clinically shown to positively impact all critical aspects of the wound healing process providing clinical and economic benefits to institutions treating acute and chronic wounds.

SOURCE Celleration, Inc.